bispecific antibodies

2:42
Mosunetuzumab individualized risk mitigation approach for NHL
Catherine Diefenbach
2:56
The exciting future of bispecific antibodies
Hermann Einsele
2:24
Immunotherapeutic approaches to myeloma
David Avigan
12:15
CAR-T vs bispecific antibodies for lymphoma
David Maloney et al.
1:10
Multiple myeloma treatment: let the war begin!
Gareth Morgan
2:30
AML: Targeting Wilms’ tumor 1 with WT1-TCB
Marion Subklewe
2:15
Targeting FLT3 in AML
Marion Subklewe
2:18
Redirecting T-cell cytotoxicity and proliferation
Marion Subklewe
2:45
Modulation of AMG 330-mediated T-cell proliferation and cytotoxicity
Marion Subklewe
11:42
AML treatment: what does the data say?
Adriano Venditti et al.
1:55
AML research at Dana-Farber: updates from Richard Stone
Richard Stone
1:36
Bispecific antibodies for R/R AML: ongoing clinical trials
John DiPersio
1:28
Bob Löwenberg’s perspective on CAR-T and immunotherapy for AML
Bob Löwenberg
2:25
Analyzing AML: novel therapies in review
Farhad Ravandi
04:22
Mohamad Mohty’s myeloma highlights from ASH 2018
Mohamad Mohty
1:40
Antibodies for AML: updates from ASH
Marina Konopleva
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals